Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  Send Message
• Download Powerpoint
• Print
• Save to my folders

  Log In with your AAAS Login

   

• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS Login

   

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

  By Richard L. Schilsky

  Science Translational Medicine23 Mar 2011 : 75cm9

  In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

  By Richard L. Schilsky

  Science Translational Medicine23 Mar 2011 : 75cm9

  In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.

  Share This Article: Copy